We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using a Point-of-Care Device.
- Authors
da Costa, Inês Anselmo; Hennenlotter, Jörg; Todenhöfer, Tilman; Neumann, Eva; Deininger, Susanne; Aufderklamm, Stefan; Bedke, Jens; Stenzl, Arnulf; Rausch, Steffen
- Abstract
Background: Prostate specific antigen (PSA) and free PSA (fPSA) are important tools for diagnosing prostate cancer (PC). Efforts are continuously undertaken to provide more patient-centered healthcare. The application of point-of-care (POC) systems for laboratory analyses represents a step in this direction. Previous investigations on total PSA measurements using a POC system (concile® O100 POC reader) showed good concordance with standard laboratory measurements. For the same POC reader a novel system for fPSA was developed. In the current study, we prospectively evaluated the quality of the POC system for fPSA. Methods: Sixty-four patients undergoing PSA measurements in our outpatient clinic between 06/2015 and 09/2015 were enrolled in the study. We measured total PSA (tPSA) and fPSA with a POC reader system (concile® O100) and a standard laboratory system (Siemens Immulite 2000®) and compared the respective results using linear regression analyses for PSA, fPSA, and fPSA/tPSA ratio (%fPSA). Results: The coefficients of determination (r²) for fPSA and %fPSA were 0.85 (p < 0.001) and 0.82 (p < 0.001) in the subgroup with total PSA between 4 and 10 ng/mL. In the subgroup with tPSA = 4 ng/mL, r² for fPSA concile® was 0.55 (p < 0.001) and 0.10 (p = 0.088) for %fPSA. In the subgroup of tPSA > 10 ng/mL the r² for fPSA and %fPSA was 0.50 (p = 0.022) and 0.50 (p = 0.022), respectively. Conclusions: The POC fPSA values correlated well with the laboratory analyses, specifically in the clinically relevant diagnostic range of tPSA 4 - 10 ng/mL. These results complement the tPSA data obtained previously and indicate the reliability of the fPSA method and the resulting %fPSA score.
- Subjects
PROSTATE-specific antigen; BIOPSY; PROSTATECTOMY; BENIGN prostatic hyperplasia; CANCER chemotherapy
- Publication
Clinical Laboratory, 2019, Vol 65, Issue 1/2, p117
- ISSN
1433-6510
- Publication type
Article
- DOI
10.7754/Clin.Lab.2018.180710